These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32064766)

  • 21. The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya.
    Roberts DA; Barnabas RV; Abuna F; Lagat H; Kinuthia J; Pintye J; Bochner AF; Forsythe S; Gomez GB; Baeten JM; John-Stewart G; Levin C
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25296. PubMed ID: 31328443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.
    Barker C; Dutta A; Klein K
    J Int AIDS Soc; 2017 Jul; 20(Suppl 4):21648. PubMed ID: 28770597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the incremental costs and savings of introducing electronic immunization registries and stock management systems: evidence from the better immunization data initiative in Tanzania and Zambia.
    Mvundura M; Di Giorgio L; Vodicka E; Kindoli R; Zulu C
    Pan Afr Med J; 2020; 35(Suppl 1):11. PubMed ID: 32373262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis.
    Larson BA; Pascoe SJS; Huber A; Long LC; Murphy J; Miot J; Fraser-Hurt N; Fox MP; Rosen S
    PLoS One; 2021; 16(3):e0248551. PubMed ID: 33735206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of facility-based HIV testing in Malawi, Zambia and Zimbabwe.
    Mwenge L; Sande L; Mangenah C; Ahmed N; Kanema S; d'Elbée M; Sibanda E; Kalua T; Ncube G; Johnson CC; Hatzold K; Cowan FM; Corbett EL; Ayles H; Maheswaran H; Terris-Prestholt F
    PLoS One; 2017; 12(10):e0185740. PubMed ID: 29036171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review.
    Mdege ND; Chindove S; Ali S
    Health Policy Plan; 2013 May; 28(3):223-36. PubMed ID: 22738755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient costs for prevention of mother-to-child HIV transmission and antiretroviral therapy services in public health facilities in Zimbabwe.
    Chingombe I; Mapingure MP; Balachandra S; Chipango TN; Gambanga F; Mushavi A; Apollo T; Suraratdecha C; Rogers JH; Ruangtragool L; Gonese E; Musuka GN; Mugurungi OM; Harris TG
    PLoS One; 2021; 16(8):e0256291. PubMed ID: 34407129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Operational characteristics of antiretroviral therapy clinics in Zambia: a time and motion analysis.
    Tampi RP; Tembo T; Mukumba-Mwenechanya M; Sharma A; Dowdy DW; Holmes CB; Bolton-Moore C; Sikazwe I; Tucker A; Sohn H
    BMC Health Serv Res; 2019 Apr; 19(1):244. PubMed ID: 31018846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costs of providing HIV care and optimal allocation of HIV resources in Guyana.
    Suraratdecha C; Stuart RM; Edwards M; Moore R; Liu N; Wilson DP; Albalak R
    PLoS One; 2020; 15(10):e0238499. PubMed ID: 33119591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Task sharing in Zambia: HIV service scale-up compounds the human resource crisis.
    Walsh A; Ndubani P; Simbaya J; Dicker P; Brugha R
    BMC Health Serv Res; 2010 Sep; 10():272. PubMed ID: 20849626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Explaining the heterogeneity in average costs per HIV/AIDS patient in Nigeria: The role of supply-side and service delivery characteristics.
    Bautista-Arredondo S; Colchero MA; Amanze OO; La Hera-Fuentes G; Silverman-Retana O; Contreras-Loya D; Ashefor GA; Ogungbemi KM
    PLoS One; 2018; 13(5):e0194305. PubMed ID: 29718906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.
    Leisegang R; Cleary S; Hislop M; Davidse A; Regensberg L; Little F; Maartens G
    PLoS Med; 2009 Dec; 6(12):e1000189. PubMed ID: 19956658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scaling-up access to antiretroviral therapy for children: a cohort study evaluating care and treatment at mobile and hospital-affiliated HIV clinics in rural Zambia.
    van Dijk JH; Moss WJ; Hamangaba F; Munsanje B; Sutcliffe CG
    PLoS One; 2014; 9(8):e104884. PubMed ID: 25122213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of antiretroviral treatment services in India: Estimated costs incurred under the National AIDS Control Programme.
    Agarwal R; Rewari BB; Shastri S; Nagaraja SB; Rathore AS
    WHO South East Asia J Public Health; 2017 Apr; 6(1):94-98. PubMed ID: 28597866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meta-analysis approach for estimating average unit costs for ART using pooled facility-level primary data from African countries.
    Cerecero-García D; Pineda-Antunez C; Alexander L; Cameron D; Martinez-Silva G; Obure CD; Marseille E; Vu L; Kahn JG; Vassall A; Gomez G; Bollinger L; Levin C; Bautista-Arredondo S
    Afr J AIDS Res; 2019 Dec; 18(4):297-305. PubMed ID: 31779577
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.